ABILIFY MAINTENATM (aripiprazole)

    Abilify Maintena  (aripiprazole for prolonged release injectable suspension) is a long acting injectable form of aripiprazole. Aripiprazole is an atypical antipsychotic. Abilify Maintena is approved for the treatment of schizophrenia in adult patients.

    Learn More

    Abilify Maintena legal logo JAN 2014 E (2)

    JINARCTM (tolvaptan)

    Jinarc (tolvaptan) is a selective vasopressin V2-receptor antagonist. It is indicated to slow the progression of kidney enlargement in patients with autosomal dominant polycystic kidney disease (ADPKD). Jinarc (tolvaptan) is available for treatment of patients with ADPKD only through a hepatic safety monitoring and distribution programme.  JINARC™ is available in weekly combination blister packs of 45+15 mg, 60+30 mg, and 90+30 mg tablets. JINARC™ treatment should be initiated and monitored by a physician experienced in the diagnosis and treatment of polycystic kidney disease.

    ABILIFY® (aripiprazole)

    Abilify (aripiprazole) is an atypical antipsychotic. It is available as tablets in strengths of 2 mg, 5 mg, 10 mg, 15 mg, and 30 mg. Abilify tablets are approved for the treatment of schizophrenia and related psychotic disorders in adults, for the treatment of manic or mixed episodes in bipolar I disorder in adults, for use as an adjunct to antidepressants for the treatment of major depressive disorder (MDD) in adult patients who had an inadequate response to prior antidepressant treatments during the current episode, for the treatment of schizophrenia in adolescents 15 – 17 years of age and for the acute treatment of manic or mixed episodes in bipolar I disorder as monotherapy in adolescent patients 13 - 17 years of age.

    Learn More

    BUSULFEX®(busulfan)

    Busulfex (busulfan) is an injectable anti-neoplastic (anti-cancer) agent. Busulfex is approved  for  use  in  combination  with other chemotherapeutic agents and/or radiotherapy as a conditioning regimen prior to hematopoietic progenitor cell transplantation, including: acute lymphocytic leukemia, acute non-lymphocytic leukemia, acute myeloid leukemia, chronic myeloid leukemia, non-Hodgkin’s lymphoma, Hodgkin’s disease, multiple myeloma, and myelodysplastic syndrome.

    Learn More

    SAMSCA® (tolvaptan)

    Samsca (tolvaptan) is a vasopressin V2-receptor antagonist. It is available as tablets in strengths of 15 mg and 30 mg. Samsca is approved for the treatment of clinically important, non-hypovolemic, hyponatremia (e.g., serum sodium < 130 mEq/L, or symptomatic hyponatremia). Samsca should be limited to use by physicians experienced in the management of clinically important hyponatremia.

    Learn More

Contact Us

1 888 997-9017
514 332-3001

Location
2250 Alfred-Nobel Boulevard,
St-Laurent, Quebec,
Suite 301
H4S 2C9


Legal